Published in J Clin Oncol on February 20, 2005
Proton Therapy for Low and Intermediate Risk Prostate Cancer (PR04) | NCT00693238
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol (2012) 1.08
Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. Radiat Oncol (2008) 0.94
Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol (2014) 0.92
Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy. Strahlenther Onkol (2009) 0.89
Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Radiat Oncol (2012) 0.87
Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. Int J Radiat Oncol Biol Phys (2015) 0.87
Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J Natl Cancer Inst Monogr (2012) 0.87
High-dose-rate brachytherapy boost for prostate cancer: rationale and technique. J Contemp Brachytherapy (2014) 0.86
Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. Curr Oncol (2010) 0.85
Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer. Prostate Cancer (2012) 0.84
Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. Strahlenther Onkol (2009) 0.83
Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer. Brachytherapy (2015) 0.82
Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2014) 0.82
Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes. J Contemp Brachytherapy (2013) 0.81
Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy (2016) 0.81
On the impact of functional imaging accuracy on selective boosting IMRT. Phys Med (2008) 0.80
High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer. Strahlenther Onkol (2010) 0.80
Dose gradient impact on equivalent dose at 2 Gy for high dose rate interstitial brachytherapy. J Contemp Brachytherapy (2012) 0.79
Proton radiation for localized prostate cancer. Nat Rev Urol (2009) 0.79
Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine. Prostate Cancer (2016) 0.78
The management of high-risk, locally advanced, prostate cancer radiation therapy. Can Urol Assoc J (2012) 0.78
The importance of local control in high-risk locally advanced prostate cancer. Curr Oncol (2012) 0.78
The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer. Radiat Oncol (2015) 0.78
Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis. Br J Cancer (2014) 0.77
Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. Can Urol Assoc J (2009) 0.76
Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity. Front Oncol (2017) 0.75
Be it resolved that in the modern era, the best method for dose escalation is brachytherapy: The con position. Can Urol Assoc J (2012) 0.75
A novel perineal shield for low-dose-rate prostate brachytherapy. J Contemp Brachytherapy (2015) 0.75
Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results. J Contemp Brachytherapy (2016) 0.75
Clinical management and burden of prostate cancer: a Markov Monte Carlo model. PLoS One (2014) 0.75
Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. Radiother Oncol (2015) 0.75
Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy. Radiat Oncol (2012) 0.75
Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know? Biomed Res Int (2016) 0.75
Radiation treatment for patients with intermediate-risk prostate cancer. Ther Adv Urol (2012) 0.75
Dosimetric evaluation of high-dose-rate interstitial brachytherapy boost treatments for localized prostate cancer. Strahlenther Onkol (2010) 0.75
Beyond prejudice: are negative evaluations the problem and is getting us to like one another more the solution? Behav Brain Sci (2012) 18.61
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol (2006) 6.24
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 5.69
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med (2010) 4.63
Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst (2002) 4.33
Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med (2004) 4.30
Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA (2004) 4.18
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42
Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr (2003) 3.34
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A (2005) 3.30
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol (2007) 3.12
Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat Med (2002) 2.90
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst (2003) 2.51
Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A (2008) 2.50
Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int (2009) 2.46
The Kitty Genovese murder and the social psychology of helping: the parable of the 38 witnesses. Am Psychol (2007) 2.23
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol (2007) 2.15
Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism (2009) 2.14
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol (2005) 2.06
Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol (2013) 1.99
Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med (2011) 1.98
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One (2010) 1.92
Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med (2008) 1.91
High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med (2014) 1.91
Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ (2005) 1.89
An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med (2006) 1.78
Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol (2006) 1.67
Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood (2004) 1.67
Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients. Int J Radiat Oncol Biol Phys (2009) 1.63
Human adrenal glands secrete vitamin C in response to adrenocorticotrophic hormone. Am J Clin Nutr (2007) 1.60
Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. J Clin Oncol (2012) 1.58
Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res (2010) 1.57
Double image encryption by using iterative random binary encoding in gyrator domains. Opt Express (2010) 1.55
Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. J Clin Oncol (2013) 1.54
Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J (2005) 1.53
Coverage with evidence development: the Ontario experience. Int J Technol Assess Health Care (2011) 1.53
Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J (2006) 1.53
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ (2004) 1.51
Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). A randomized controlled trial. Thromb Haemost (2008) 1.50
Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet (2012) 1.49
Using administrative databases to measure waiting times for patients undergoing major cancer surgery in Ontario, 1993-2000. Can J Surg (2005) 1.49
Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ (2004) 1.46
Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 1.46
Intravenously administered vitamin C as cancer therapy: three cases. CMAJ (2006) 1.43
Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell (2007) 1.41
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. J Clin Oncol (2005) 1.40
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One (2012) 1.35
Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J Clin Invest (2010) 1.33
Significant association with location of central venous line placement and risk of venous thrombosis in children. Thromb Haemost (2005) 1.32
An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res (2003) 1.29
Comparison of the genomic structure and variation in the two human sodium-dependent vitamin C transporters, SLC23A1 and SLC23A2. Hum Genet (2004) 1.27
Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med (2011) 1.27
Registries that show efficacy: good, but not good enough. J Clin Oncol (2008) 1.25
Lessons learned from the Decision Board: a unique and evolving decision aid. Health Expect (2000) 1.25
Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem (2009) 1.20
An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res (2003) 1.20
Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol (2012) 1.19
Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol (2011) 1.17
6-Bromo-6-deoxy-L-ascorbic acid: an ascorbate analog specific for Na+-dependent vitamin C transporter but not glucose transporter pathways. J Biol Chem (2004) 1.16
Genomic and functional analysis of the sodium-dependent vitamin C transporter SLC23A1-SVCT1. Genes Nutr (2007) 1.16
Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J (2010) 1.16
The adenylyl cyclase activity of anthrax edema factor. Mol Aspects Med (2009) 1.15
Effect of hepatocyte apoptosis induced by TNF-alpha on acute severe hepatitis in mouse models. World J Gastroenterol (2000) 1.14
Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist (2003) 1.13
Flavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isoform 2 (GLUT2), intestinal transporters for vitamin C and Glucose. J Biol Chem (2002) 1.13
Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. Can J Surg (2006) 1.12
High-dose oral vitamin C partially replenishes vitamin C levels in patients with Type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol (2005) 1.11
Standard-dose vs high-dose multivitamin supplements for HIV. JAMA (2013) 1.08
Genetic variation in the sodium-dependent vitamin C transporters, SLC23A1, and SLC23A2 and risk for preterm delivery. Am J Epidemiol (2005) 1.08
Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect (2009) 1.07
Radiation therapy and tamoxifen: concurrent or sequential? That is the question. J Clin Oncol (2004) 1.06
Cloning and functional characterization of the mouse fructose transporter, GLUT5. Biochim Biophys Acta (2002) 1.05
On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol (2010) 1.05
Apoptosis antagonizing transcription factor protects renal tubule cells against oxidative damage and apoptosis induced by ischemia-reperfusion. J Am Soc Nephrol (2006) 1.04
Factors that predict risk of thrombosis in relatives of patients with unprovoked venous thromboembolism. Chest (2009) 1.03
A promoter recognition mechanism common to yeast mitochondrial and phage t7 RNA polymerases. J Biol Chem (2009) 1.03
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood (2008) 1.03
Conservative and dietary interventions for cancer-related lymphedema: a systematic review and meta-analysis. Cancer (2010) 1.02
Invasive endocervical adenocarcinoma: proposal for a new pattern-based classification system with significant clinical implications: a multi-institutional study. Int J Gynecol Pathol (2013) 0.99
Hemoglobin and plasma vitamin C levels in patients on peritoneal dialysis. Perit Dial Int (2010) 0.99
Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood (2006) 0.98
The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy. Am J Hum Genet (2005) 0.98
Imaging characteristics of a novel technetium Tc 99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients With acute deep vein thrombosis or a history of deep vein thrombosis. Arch Intern Med (2003) 0.97
Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal (2013) 0.97
Vitamins C and E and the prevention of preeclampsia. N Engl J Med (2006) 0.96
Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem (2010) 0.96
Genetic variation in sodium-dependent vitamin C transporters SLC23A1 and SLC23A2 and risk of advanced colorectal adenoma. Nutr Cancer (2008) 0.96
Reproducibility of the histological diagnosis of cervical dysplasia among pathologists from 4 continents. Int J Gynecol Pathol (2008) 0.94
PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein. J Biol Chem (2005) 0.94